Banque Pictet & Cie SA Has $77.33 Million Stock Position in AbbVie Inc. $ABBV

Banque Pictet & Cie SA grew its stake in shares of AbbVie Inc. (NYSE:ABBV) by 89.2% during the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 333,971 shares of the company’s stock after buying an additional 157,480 shares during the quarter. AbbVie makes up 0.4% of Banque Pictet & Cie SA’s holdings, making the stock its 23rd biggest holding. Banque Pictet & Cie SA’s holdings in AbbVie were worth $77,328,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of ABBV. Marshall & Sullivan Inc. WA bought a new position in AbbVie in the second quarter valued at about $25,000. Evolution Wealth Management Inc. acquired a new position in shares of AbbVie in the second quarter valued at approximately $26,000. Spurstone Advisory Services LLC bought a new position in AbbVie in the 2nd quarter valued at approximately $28,000. Financial Gravity Companies Inc. acquired a new stake in AbbVie during the 2nd quarter worth approximately $36,000. Finally, Delos Wealth Advisors LLC acquired a new stake in AbbVie during the 2nd quarter worth approximately $39,000. 70.23% of the stock is currently owned by institutional investors.

AbbVie Trading Down 0.5%

ABBV stock opened at $228.55 on Friday. The firm has a market cap of $403.94 billion, a PE ratio of 173.14, a price-to-earnings-growth ratio of 1.30 and a beta of 0.36. The stock has a 50-day moving average price of $226.66 and a 200-day moving average price of $213.48. AbbVie Inc. has a 1-year low of $164.39 and a 1-year high of $244.81.

AbbVie (NYSE:ABBV) last released its earnings results on Friday, October 31st. The company reported $1.86 EPS for the quarter, topping the consensus estimate of $1.77 by $0.09. The business had revenue of $15.78 billion during the quarter, compared to analysts’ expectations of $15.58 billion. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The firm’s revenue was up 9.1% on a year-over-year basis. During the same quarter last year, the firm posted $3.00 earnings per share. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be paid a $1.73 dividend. The ex-dividend date is Friday, January 16th. This represents a $6.92 annualized dividend and a dividend yield of 3.0%. This is an increase from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s dividend payout ratio (DPR) is presently 496.97%.

Analyst Ratings Changes

ABBV has been the subject of several recent research reports. UBS Group upped their price target on shares of AbbVie from $195.00 to $220.00 and gave the company a “neutral” rating in a research report on Friday, November 7th. Wells Fargo & Company increased their price objective on AbbVie from $240.00 to $260.00 and gave the company an “overweight” rating in a report on Friday, September 12th. Wall Street Zen raised AbbVie from a “buy” rating to a “strong-buy” rating in a report on Saturday, December 13th. Morgan Stanley upped their price target on AbbVie from $261.00 to $269.00 and gave the company an “overweight” rating in a research report on Friday, December 12th. Finally, Citigroup lowered their price objective on AbbVie from $240.00 to $235.00 and set a “neutral” rating for the company in a research report on Monday, November 3rd. Three analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $245.84.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.